Lanean...
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...
Gorde:
| Argitaratua izan da: | Leuk Lymphoma |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4950458/ https://ncbi.nlm.nih.gov/pubmed/27118119 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2016.1160082 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|